Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A regulatory breakdown of vaginal estradiol compounding legality under FDA 503A and 503B frameworks, how compounded products differ from FDA-approved formulations, and current safety and labeling requirements.
Read clinical reviewA clinical review of FDA Adverse Event Reporting System (FAERS) data for vaginal estradiol, including signal detection, label updates, and real-world safety evidence from post-market surveillance.
Read clinical reviewFull FDA approval history for vaginal estradiol products including Estrace Cream, Vagifem, Estring, and Imvexxy. Label requirements, boxed warning context, and post-market safety data.
Read clinical reviewA comprehensive review of every FDA label change for vaginal estradiol products from 2020 through 2026, including boxed warning revisions, new safety data, and clinical implications for prescribers and patients.
Read clinical reviewHow the FDA and EMA differ on vaginal estradiol approval, labeling, safety monitoring, and prescribing guidance for genitourinary syndrome of menopause.
Read clinical reviewA clinical review of vaginal estradiol's FDA approval history, patent disputes, generic competition, and evolving labeling requirements for vulvovaginal atrophy treatment.
Read clinical review